2014 Annual Report now available on new website www.celyad.com

Mont-Saint-Guibert, Belgium - Cardio3 BioSciences (“the Company”) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of engineered cell therapies, today announced that all resolutions presented at the Company’s Annual Shareholder Assembly were duly passed at the meeting, which was held today at 09:00 CET.

As a result, the Company’s proposed name change to “Celyad” is now confirmed, effective immediately. The new corporate website is available online at www.celyad.com. Furthermore, as of 09:00 CET on 6 May 2015, the Company will trade on the Euronext Brussels and Paris regulated markets under the symbol CYAD, replacing former symbol CARD. No specific action is required from our shareholders following this symbol change.

The Company is also pleased to announce that copies of the 2014 Annual Report and Accounts will be made available to shareholders on the "Investors" section of the Company's website at www.celyad.com, and paper copies will be made available upon request to the Company.

To read the NL version, please click here

Download press release(s)

Communiqué de presse

654.00 Ko

Press release

409.67 Ko

About Celyad

Developing breakthrough pioneering therapies for life-threatening diseases.

Celyad is a biopharmaceutical company, specialized in cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis. Our scientific approach is inspired by the natural mechanisms that are used by the body to fight disease.

Read more about Celyad

Celyad announces filing of registration statement in the United States for a proposed glob...

Next News

Celyad announces filing of registration statement in the United States for a proposed glob...